– COVID Treatment: Pfizer to price Covid treatment Paxlovid at $1,390 per course

Pfizer on Wednesday stated it’ll set the US worth for its Covid-19 antiviral therapy Paxlovid at almost $1,400 per five-day course when it strikes to business gross sales after authorities shares run out, greater than double what the federal government at present pays for it.
The brand new checklist worth, which doesn’t embody rebates and different reductions to insurers and pharmacy profit managers, is $1,390 per course, Pfizer stated in an emailed assertion. The US authorities paid round $530 per course for Paxlovid it has made out there to Individuals for gratis.
Paxlovid, probably the most generally prescribed at house therapy for Covid-19 within the US, will stay out there free of charge to sufferers there till the tip of the 12 months, Pfizer stated.
Underneath an settlement with the federal government, the drug may even keep freed from cost for sufferers insured underneath the Medicare and Medicaid packages via the tip of 2024, and to uninsured and underinsured sufferers via 2028.
In Pfizer’s scientific trial, Paxlovid was proven to scale back hospitalizations and demise by round 90% for unvaccinated individuals in danger for severe illness. In one other trial, Pfizer was not capable of present profit for these thought of at commonplace danger, together with vaccinated sufferers.
Influential US drug pricing watchdog the Institute for Scientific and Financial Assessment (ICER) stated final 12 months that its recommended worth vary for Paxlovid primarily based on the advantages and worth to sufferers was between $563 to $906 per course.
America bought round 24 million programs of the oral two-drug therapy from Pfizer, and nonetheless had a big provide, however organized to return 7.9 million programs final week. The corporate additionally slashed its full-year income forecast because of lower-than-expected gross sales of its Covid-19 merchandise.
Underneath that deal, a credit score for the returned Paxlovid doses can pay for the provision to Medicare, Medicaid, underinsured and uninsured sufferers.
Demand for the drug has fallen since final 12 months. In 2022, sufferers got round 7 million programs of the drug, in accordance with US authorities knowledge. By means of October 1, round 3.4 million programs had been administered in 2023.
The brand new checklist worth was first reported by the Wall Road Journal.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button